On August 6, Zoetis rose 6.99% in regular trading, trading at $73.97/share, with turnover of $175 million. The rally was driven by the company's Q2 earnings report, in which adjusted EPS of $1.87 slightly beat the consensus estimate of $1.86, representing a 6.25% year-over-year increase.

Revenue of $2.468 billion came in below the $2.502 billion estimate and was flat year-over-year. The company simultaneously slashed its full-year adjusted EPS guidance to $6.15-$6.25, well below the prior range of $6.85-$7.00 and the analyst consensus of $6.87. Full-year revenue guidance was also cut to $9.12-$9.32 billion versus the prior $9.68-$9.96 billion outlook. Management cited increased pricing sensitivity among pet owners and reduced veterinary clinic visits as key headwinds.

However, shares had already plunged over 30% since Q1 results missed expectations and the company first lowered guidance, with multiple investment banks cutting price targets to the $80-$85 range. With significant pessimism already priced in, the marginal EPS beat served as a catalyst for an oversold bounce. On the earnings call, executives clarified that current pricing investments through rebates and point-of-sale programs are targeted and time-limited rather than permanent structural changes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)